Drug intelligence / Profile preview

cannabis extract + delta-9-tetrahydrocannabinol + cannabidiol

Development stage: Phase 3
Lead developer: Deutsches Zentrum für Medizinal Cannabis
Modality: Small Molecules
Administration: Oral

Overview

Cannabis extract + THC + CBD (specifically in a 10:10 ratio) is a medicinal cannabis-derived botanical combination containing standardized amounts of the phytocannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). It is currently being investigated in a prospective observational study in Germany, sponsored by the Deutsches Zentrum für Medizinal Cannabis, for the treatment of non-motor symptoms of Parkinson's disease, such as pain, sleep disorders, depression, stress, and anxiety. The drug functions by modulating the endocannabinoid system, primarily acting as an agonist at the cannabinoid receptors CB1 and CB2. As a plant-derived extract, it is classified as a botanical product and is used in clinical settings as a medicinal cannabis preparation rather than a traditionally approved pharmaceutical product.

Other names: medicinal cannabis extractcannabis-derived combination extractCannabis extract + THC + CBD

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)ENT1 (Solute carrier family 29 member 1)GPR55 (G protein-coupled receptor 55)GLRA1/GLRA3 (Glycine receptor subunit alpha-1 (GLRA1) and Glycine receptor subunit alpha-3 (GLRA3))PPARG (Peroxisome proliferator-activated receptor gamma)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on cannabis extract + delta-9-tetrahydrocannabinol + cannabidiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabis extract + delta-9-tetrahydrocannabinol + cannabidiol.